Transcatheter Heart Valve Design and Mortality: Truth or Dare?
Since the early stages of development, transcatheter deployment of an aortic bioprosthetic valve required either a balloon-expandable or a self-expandable delivery concept. Consequently, two device types have been considered the main players in transcatheter aortic valve replacement (TAVR) for many years: the balloon-expandable Edwards SAPIEN valve (BEV) family (Edwards Lifesciences, Irvine, CA, USA) and the self-expandable Medtronic CoreValve (SEV) family (Medtronic Inc., Minneapolis, MN, USA). Both device types have been continuously refined to improve ease of use and decrease peri-procedural complications, and both technologies have been associated with favorable short- and long-term outcomes when compared with surgical aortic valve replacement in randomized clinical trials (1). Very recently, the current generation BEV (SAPIEN 3, Edwards Lifesciences) and SEV (Evolut, Medtronic) have been approved by the Food and Drug Administration for selected low-risk patients with severe symptomatic aortic stenosis. Very few randomized head-to-head trials between both device technologies have been performed to date (2,3), although numerous comparisons from various registry analyses have been published (4,5). Despite the inherent differences in expansion mode, stent frame and leaflet characteristics between both device types, which do translate into some differences in hemodynamic function, paravalvular sealing and peri-procedural complications, clinical outcomes and particularly mortality have been always considered comparable (1-5).